Hemcheck’s new product for the blood gas market is now CE marked. The bgs-Test is a hemolysis test which can receive a significantly larger amount of blood volume compared to current tests, fully functioning as an airtight cap for blood gas syringes, while allowing for air venting, which means many advantages for users.
The CE-marking is a pre-condition for the product to be sold in the European market, and it’s the result of a series of processes and work steps including user-, technical-, regulatory- and safety requirements, user tests, etc.
– There is a lot of work behind the CE-marking and I am very happy that we now have finalised this project, where everybody in our team have been involved. The sales and marketing efforts can now be initiated, even though many potential customers have known that we have been developing the product. We will shortly initiate clinical tests together with possible customers and we look forward to start marketing the product, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.